Personalized Medicine for Breast Cancer | Prevention 3rats & Treatment 3rats | Robb Report - The Global Luxury Source
This is part three in our special report series on breast cancer in honor of October s Breast Cancer Awareness month. In this article, we hear from two award-winning scientists: James Hicks, PhD, of the Cold Spring Harbor Laboratory, and Peter Kuhn, PhD, of the University 3rats of Southern 3rats California. 3rats Both work with the Breast Cancer Research Foundation (BCRF) on the cutting edge of using personalized 3rats medicine to treat and diagnose breast cancer. 3rats
KUHN: The practice of medicine has always been personalized through the patient physician interaction, but the technologies have not been able to provide truly biologically informed, complete knowledge of the disease at every point in time of its progression. It is the latter that we need to bring to breast-cancer care.
HICKS: In every clinical trial there are patients who respond well and those who do not. Personalized treatment results when you know ahead of time which patients will respond best to a particular treatment. The goal is to find characteristics 3rats that mark certain cases as potential responders to specific treatments. Breast cancer currently has two strong drivers: expression of the estrogen receptor in about 50 percent of cases, leading to treatments 3rats focused 3rats on that hormone, and overexpression of the HER2/neu protein in another 25 percent, which indicates treatment with drugs, 3rats such as Herceptin, that block that growth pathway. But neither treatment is 100 percent successful, and 25 percent of patients have triple negative disease, meaning they lack both biomarkers, so more work needs to be done.
We also know that cancers can change as they progress, so decisions made by testing a single surgical sample at the beginning of treatment may not be relevant 3rats a few months or years later. The breakthrough potential of the fluid biopsy is that through repeated tests, using a simple blood draw, we can follow the changes in a cancer in real time and adjust treatments to target the altered cells.
This is the final report in our four-part series on the cutting edge of research for treating and...
Read Article
canadian orders | international orders
Luxury Newswire 3rats Robb Report Video Advanced Search New & Noteworthy Luxury Properties Private Aviation Advisory Board Past Issues Best of the Best Robb Report 3rats iPad Edition Digital Editions Archive Subscribe to Robb Report
Automobiles Travel Aviation Wine, Spirits & Cigars Jewelry Fashion Boating & Yachting Watches Home Design Real Estate Electronics Dining Private Aviation Forum Robb Vices Sports 3rats & Leisure Health & Wellness
Robb Report Robb Report iPad Edition Collection Health & Wellness Home & Style Host s Guide Watch Collector Private Aviation Sourcebook Robb Vices Robb Report Arabia Robb Report Brazil Robb Report China Robb Report India Robb Report Kazakhstan Robb Report Russia Robb Report Singapore Robb Report Spain Robb Report Turkey Robb Report Vietnam 3rats Digital Editions
Advertise About Us Terms & Conditions RSS Contact Us Reprints eNewsletter International Partners Like Robb Report on Facebook Follow Robb Report on Twitter Robb Report on Pinterest News & Press Privacy Policy Career Opportunities
This is part three in our special report series on breast cancer in honor of October s Breast Cancer Awareness month. In this article, we hear from two award-winning scientists: James Hicks, PhD, of the Cold Spring Harbor Laboratory, and Peter Kuhn, PhD, of the University 3rats of Southern 3rats California. 3rats Both work with the Breast Cancer Research Foundation (BCRF) on the cutting edge of using personalized 3rats medicine to treat and diagnose breast cancer. 3rats
KUHN: The practice of medicine has always been personalized through the patient physician interaction, but the technologies have not been able to provide truly biologically informed, complete knowledge of the disease at every point in time of its progression. It is the latter that we need to bring to breast-cancer care.
HICKS: In every clinical trial there are patients who respond well and those who do not. Personalized treatment results when you know ahead of time which patients will respond best to a particular treatment. The goal is to find characteristics 3rats that mark certain cases as potential responders to specific treatments. Breast cancer currently has two strong drivers: expression of the estrogen receptor in about 50 percent of cases, leading to treatments 3rats focused 3rats on that hormone, and overexpression of the HER2/neu protein in another 25 percent, which indicates treatment with drugs, 3rats such as Herceptin, that block that growth pathway. But neither treatment is 100 percent successful, and 25 percent of patients have triple negative disease, meaning they lack both biomarkers, so more work needs to be done.
We also know that cancers can change as they progress, so decisions made by testing a single surgical sample at the beginning of treatment may not be relevant 3rats a few months or years later. The breakthrough potential of the fluid biopsy is that through repeated tests, using a simple blood draw, we can follow the changes in a cancer in real time and adjust treatments to target the altered cells.
This is the final report in our four-part series on the cutting edge of research for treating and...
Read Article
canadian orders | international orders
Luxury Newswire 3rats Robb Report Video Advanced Search New & Noteworthy Luxury Properties Private Aviation Advisory Board Past Issues Best of the Best Robb Report 3rats iPad Edition Digital Editions Archive Subscribe to Robb Report
Automobiles Travel Aviation Wine, Spirits & Cigars Jewelry Fashion Boating & Yachting Watches Home Design Real Estate Electronics Dining Private Aviation Forum Robb Vices Sports 3rats & Leisure Health & Wellness
Robb Report Robb Report iPad Edition Collection Health & Wellness Home & Style Host s Guide Watch Collector Private Aviation Sourcebook Robb Vices Robb Report Arabia Robb Report Brazil Robb Report China Robb Report India Robb Report Kazakhstan Robb Report Russia Robb Report Singapore Robb Report Spain Robb Report Turkey Robb Report Vietnam 3rats Digital Editions
Advertise About Us Terms & Conditions RSS Contact Us Reprints eNewsletter International Partners Like Robb Report on Facebook Follow Robb Report on Twitter Robb Report on Pinterest News & Press Privacy Policy Career Opportunities
No comments:
Post a Comment